Cambrex

Activities: Ingredients

Trending Articles

  1. ten23 health QC lab to support commercial product testing for US customer following FDA approvals This pivotal regulatory milestone enables FDA-compliant release and stability testing for injectable drug products throughout the clinical and commercial phases, in addition to...
  2. Novo Nordisk wins positive ruling for semaglutide compound patent from China’s Supreme People’s Court The company has welcomed a decision by China’s Supreme People’s Court affirming the validity of its semaglutide compound patent, strengthening confidence for foreign...
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Building a beta-lactam powerhouse: Gaelic’s strategic leap with Athlone In December 2025, Gaelic Laboratories, a world-class manufacturer of beta-lactam (penicillin) products, acquired Athlone Laboratories, another leading developer and supplier of...
  4. Zephyrus Innovations receives 510(k) clearance from FDA for VaporShield CSTD With CSTDs now required in the US under USP legislation, VaporShield is the first direct injection CSTD for subcutaneous and intramuscular administration
  5. A new era in diabetes: five biotech companies moving past daily insulin injections From cell-encapsulation platforms and islet transplantation breakthroughs to next-generation GLP-1 combinations and connected insulin delivery, a new wave of biotech innovation...

Upcoming event

From powder to granules: a deep dive into wet granulation methods

14 January 2026 | Virtual See all

Related Content

Finance

Cambrex unveils $120m investment to expand API manufacturing and strengthen US drug supply resilience

Cambrex's continued investments underscore its commitment to adding capabilities and increasing capacity to meet the evolving needs and growing demand of the pharmaceutical industry.
Manufacturing

Cambrex optimises the peptide synthesis process with novel LPPS technology

The manufacturing solution reduces the reliance on specialised, solid-phase reactors, while being easily scalable and less resource-intensive
Distribution

Cambrex expands stability storage capabilities with novel US facility

The facility allows for pharmaceutical and medical device storage at a wide range of temperatures and humidity levels, serving the US market with next day delivery
Manufacturing

Cambrex completes expansion at small molecule API facility

The company has announced it has doubled the size of its small molecule active pharmaceutical ingredient (API) manufacturing facility
Manufacturing

Cambrex completes Snapdragon Chemistry acquisition

The company continues to expand its portfolio of specialised solutions for pharmaceutical development and manufacturing
Manufacturing

Cambrex set to acquire Snapdragon Chemistry

“The acquisition of Snapdragon will accelerate our growth in the area of continuous flow process development and manufacturing"
Manufacturing

Cambrex invests in 21,000 sqft R&D facility in Minnesota

The facility is located on a 45-acre property and produces a wide range of APIs and pharmaceutical intermediates, including highly potent molecules and controlled substances
Subscribe now